UNSPSC 51111600: Antimetabolites

This classification denotes drugs that are chemically similar to naturally occurring metabolites, but differ enough to interfere with normal metabolic pathways.

UNSPSC 51111600 Antimetabolites is a Class code covering pharmaceutical products used in cancer chemotherapy and other clinical applications that state and local health agencies and Medicaid programs acquire for direct use or distribution through pharmacy benefit channels. Recent state procurement activity shows health and human services agencies exploring direct-to-manufacturer acquisition models to manage costs and improve prescription fulfillment efficiency outside traditional pharmacy benefit manager and group purchasing organization intermediaries. The code captures what state health departments, Medicaid agencies, and regional health authorities actually procure—chemotherapy drugs and related antimetabolite medications—when those acquisitions are sourced or managed through direct contracting arrangements rather than through standard pharmaceutical wholesale distribution.

State health and human services commissions drive solicitation activity under this code. The Texas Health and Human Services Commission issued a Request for Information (RFI) in April 2026 to gather vendor capabilities and market intelligence regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking vendors experienced with direct contracting for self-insured employers and health plans in both private and government sectors, flexibility to negotiate contracts based on net pricing models without rebates, and capability to implement outcomes-based agreements. The RFI represents preliminary market research before formal procurement, with no award value, budget range, or set-aside designations specified at this stage. Recent documented activity concentrates in Texas; broader geographic spread and repeat-buyer patterns are not evident from the current opportunity record.